4-(5-phenyl-benzoxazol-2-yl)-aniline | 313527-64-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(5-phenyl-benzoxazol-2-yl)-aniline
• 英文别名: 4-(5-Phenyl-benzoxazol-2-yl)-anilin；4-(5-phenyl-benzooxazol-2-yl)-phenylamine；4-(5-Phenyl-1,3-benzoxazol-2-yl)aniline
• CAS: 313527-64-9
• 化学式: C₁₉H₁₄N₂O
• 分子量: 286.333
• InChiKey: KVOKKKTWVOCLGO-UHFFFAOYSA-N

物化性质

• 熔点：
  174.2 °C
• 沸点：
  478.8±28.0 °C(Predicted)
• 密度：
  1.231±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(5-phenyl-benzoxazol-2-yl)-aniline 在 盐酸 作用下， 生成 4-(5-phenyl-benzoxazol-2-yl)-benzenediazonium; chloride-hydrochloride
  参考文献：
  名称：

  The Synthesis of Certain Phenylated Benzoxazoles and Derivatives¹

  摘要：

  DOI：

  10.1021/ja01314a023
• 作为产物：
  描述：

  4-nitro-benzoic acid-(3-nitro-biphenyl-4-yl ester) 在 盐酸 、 溶剂黄146 、 tin(ll) chloride 作用下， 生成 4-(5-phenyl-benzoxazol-2-yl)-aniline
  参考文献：
  名称：

  The Synthesis of Certain Phenylated Benzoxazoles and Derivatives¹

  摘要：

  DOI：

  10.1021/ja01314a023

文献信息

• Small molecule inhibition of microRNA-21 expression reduces cell viability and microtumor formation
  作者：Nicholas Ankenbruck、Rohan Kumbhare、Yuta Naro、Meryl Thomas、Laura Gardner、Cole Emanuelson、Alexander Deiters

  DOI：10.1016/j.bmc.2019.05.044

  日期：2019.8

  one of the most established oncogenic miRNAs, is found to be upregulated in a wide range of cancers making it an attractive therapeutic target. Employment of a luciferase-based live-cell reporter assay in a high-throughput screen of >300,000 small molecules led to the discovery of a new class of ether-amide miR-21 inhibitors. Following a structure-activity relationship study, an optimized lead molecule

  MicroRNA（miRNA）是短的非编码RNA分子，估计可调节大量蛋白质编码基因的表达，并与多种生物学过程有关，例如发育，分化，增殖和细胞存活。miRNA的失调归因于各种人类疾病（包括癌症）的发作和发展。发现MicroRNA-21（miR-21）是最成熟的致癌miRNA之一，在多种癌症中均被上调，使其成为有吸引力的治疗靶标。在> 300,000个小分子的高通量筛选中使用基于荧光素酶的活细胞报告基因测定法，导致发现了一类新型的醚酰胺miR-21抑制剂。经过结构-活性关系研究，发现优化的前导分子可抑制miR-21转录。此外，该抑制剂通过诱导凋亡在宫颈癌细胞系中显示出细胞毒性，并且在长期的克隆形成测定中能够减少微肿瘤的形成。总而言之，这项工作报告了一种新的miR-21小分子抑制剂的发现，并证明了其作为癌症治疗替代方法的潜力。
• 트리벤즈아졸 아민 유도체 및 이를 포함한 유기 전계 발광 소자
  申请人：Lapto Co., Ltd. 주식회사 랩토(120120213992) Corp. No ▼ 131111-0274298BRN ▼129-86-56546

  公开号：KR102059550B1

  公开（公告）日：2019-12-26

  UV영역의 고에너지 외부 광원을 효과적으로 흡수하여 유기 전계 발광 소자 내부의 유기물들의 손상을 최소화함으로써 유기 전계 발광 소자의 실질적인 수명 향상에 기여하는 트리벤즈아졸 아민 유도체를 제공한다. 본 발명에 따른 유기 전계 발광 소자는, 제1 전극; 제2 전극; 및 상기 제1 전극과 제2 전극 사이에 배치된 유기물층; 제2 전극 상에 배치된 캡핑층;을 포함하고, 상기 캡핑층은 하기 화학식 1로 표시되는 트리벤즈아졸 아민 유도체를 포함한다.[화학식 1] (상기 화학식 1에 있어서, R1, R2 및 R3은 서로 같거나 상이하고, 각각 독립적으로 수소; 탄소수 1~10의 알킬기;이고, l, n 및 m은 0 내지 4의 정수임.)

  这段文本描述了一种提供三苯并嗪胺衍生物的有机电致发光器件，通过有效吸收UV区域的高能外部光源，最小化有机物在有机电致发光器件内部的损伤，从而提高有机电致发光器件的实际寿命。根据本发明，有机电致发光器件包括第一电极；第二电极；以及位于所述第一电极和第二电极之间的有机层；位于所述第二电极上的封装层；其中所述封装层包括用化学式1表示的三苯并嗪胺衍生物。【化学式1】（在上述化学式1中，R1、R2和R3可以相同也可以不同，分别独立地表示氢、含有1~10个碳的烷基；l、n和m是0到4的整数。）
• Substituted heteroaryl- and phenylsulfamoyl compounds
  申请人：Hamanaka S. Ernest

  公开号：US20050228015A1

  公开（公告）日：2005-10-13

  The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环和苯基磺酰胺化合物，含有这些化合物的制药组合物以及将这些化合物用作过氧化物酶增殖子激活受体（PPAR）激动剂。PPARα激动剂，含有这些化合物的制药组合物以及使用这些化合物以提高某些血浆脂质水平，包括高密度脂蛋白胆固醇和降低其他某些血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，从而治疗由低高密度脂蛋白胆固醇水平和/或高低密度脂蛋白胆固醇和甘油三酯水平加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中。这些化合物还可用于治疗反能量平衡（NEB）和反刍动物相关疾病。
• Substituted Heteroaryl- and Phenylsulfamoyl Compounds
  申请人：Hamanaka S. Ernest

  公开号：US20060258723A1

  公开（公告）日：2006-11-16

  The present invention is directed at substituted heteroaryl and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator actuator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

  本发明涉及取代杂环芳基和苯磺酰胺化合物，含有这种化合物的制药组合物以及将这种化合物用作过氧化物酶体增殖激活受体（PPAR）激动剂。PPARα激动剂，含有这种化合物的制药组合物以及将这种化合物用于升高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低某些其他血浆脂质水平，如LDL胆固醇和甘油三酯，因此治疗低HDL胆固醇水平和/或高LDL胆固醇和甘油三酯水平加剧的疾病，例如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中使用。这些化合物也适用于治疗反式能量平衡（NEB）和反刍动物相关疾病。
• US7262318B2
  申请人：——

  公开号：US7262318B2

  公开（公告）日：2007-08-28